Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

NCT07287137 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

COVID -19
COVID - 19
COVID 19
Influenza
Respiratory Virus
Respiratory Viruses
Respiratory Virus Infection
Respiratory Virus Infections

Interventions

DRUG: Pfizer-BioNTech mRNA COVID-19 vaccine
DRUG: Novavax recombinant protein vaccine

Sponsor

Henry M. Jackson Foundation for the Advancement of Military Medicine

Collaborators

[object Object]
[object Object]